SynthesisBMC cancer2019
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
Synthesis in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis.Frontiers in pharmacology · 2024Pooled it
- Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.Disease markers · 2022Pooled it
- DNA methylation signatures of sporadic colorectal cancer with microsatellite instability.Epigenetics · 2026Article
- Emerging Molecular Insights and Targeted Therapeutics in Colorectal Cancer: From Emerging Approaches to Personalized Medicine.Journal of gastrointestinal cancer · 2026Review
- Rectal Neuroendocrine Tumours: A 10-Year Review of Clinical Presentation, Pathological Features, and Treatment Outcomes from a Tertiary Care Cancer Centre in Western India.Indian journal of surgical oncology · 2026Article
- Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.Frontiers in pharmacology · 2026Review
- A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes.Cancers · 2023Review
- Genetic heterogeneity of colorectal cancer and the microbiome.World journal of gastrointestinal oncology · 2023Review
- Review
- Article
- Article
- NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis.International journal of molecular sciences · 2022Review
- Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.Pathology oncology research : POR · 2022Review
- NOP14 regulates the growth, migration, and invasion of colorectal cancer cells by modulating the NRIP1/GSK-3β/β-catenin signaling pathway.European journal of histochemistry : EJH · 2021Article
- Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions.Cancers · 2021Article
- Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.Frontiers in oncology · 2021Review
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundCpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis.
methodsWe searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques.
resultsThe pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21-24%; I
conclusionAlthough no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.